GB0901411D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB0901411D0
GB0901411D0 GB0901411A GB0901411A GB0901411D0 GB 0901411 D0 GB0901411 D0 GB 0901411D0 GB 0901411 A GB0901411 A GB 0901411A GB 0901411 A GB0901411 A GB 0901411A GB 0901411 D0 GB0901411 D0 GB 0901411D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0901411A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Priority to GB0901411A priority Critical patent/GB0901411D0/en
Publication of GB0901411D0 publication Critical patent/GB0901411D0/en
Application status is Ceased legal-status Critical

Links

GB0901411A 2009-01-29 2009-01-29 Treatment Ceased GB0901411D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0901411A GB0901411D0 (en) 2009-01-29 2009-01-29 Treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0901411A GB0901411D0 (en) 2009-01-29 2009-01-29 Treatment
PCT/GB2010/000153 WO2010086617A2 (en) 2009-01-29 2010-01-29 Treatment
GB201001521A GB2467437A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in the treatment of tularemia

Publications (1)

Publication Number Publication Date
GB0901411D0 true GB0901411D0 (en) 2009-03-11

Family

ID=40469217

Family Applications (2)

Application Number Title Priority Date Filing Date
GB0901411A Ceased GB0901411D0 (en) 2009-01-29 2009-01-29 Treatment
GB201001521A Withdrawn GB2467437A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in the treatment of tularemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB201001521A Withdrawn GB2467437A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in the treatment of tularemia

Country Status (2)

Country Link
GB (2) GB0901411D0 (en)
WO (1) WO2010086617A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5666A (en) 1848-07-11 Machinery for sawing irregular shapes
US153A (en) 1837-03-25 Peters
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein Immunogenic membrane protein complex, seen for the front up and tell priority over derav as immune stimulant and as vaccine
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5308854A (en) 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5192668A (en) 1990-10-11 1993-03-09 Merck & Co., Inc. Synthesis of protease inhibitor
US5187074A (en) 1990-10-11 1993-02-16 Merck & Co., Inc. Method of hydroxylation with ATCC 55086
WO1993008184A1 (en) 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
SG90042A1 (en) 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
AT157882T (en) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0 deazylierte monophosphoryl lipid A containing vaccine compositions
WO1995010281A1 (en) 1993-10-13 1995-04-20 Merck & Co., Inc. Combination therapy for hiv infection
JP3967769B2 (en) 1993-11-17 2007-08-29 オーエム・ファルマ Glucosamine disaccharide, their preparation, pharmaceutical compositions containing them and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5476874A (en) 1994-06-22 1995-12-19 Merck & Co., Inc. New HIV protease inhibitors
CN1289065C (en) 1995-04-25 2006-12-13 史密斯克莱·比奇曼生物公司 Vaccine containing saponin and sterol
US5846978A (en) 1996-05-02 1998-12-08 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999064301A1 (en) 1998-06-08 1999-12-16 Sca Emballage France Fast flattening packaging
DE69935330T2 (en) 1998-06-30 2007-10-31 Om Pharma New acylated pseudodipeptides, methods for their manufacture, and pharmaceutical compositions containing them
FR2782721B1 (en) 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Phosphohalohydrin new compounds, and method for making applications
ES2228497T3 (en) 1999-04-19 2005-04-16 Glaxosmithkline Biologicals S.A. adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
AT411805T (en) * 2001-07-20 2008-11-15 Bioagency Ag Organo-phosphorus compounds for the activation of gamma / delta T cells
WO2005021708A2 (en) * 2003-05-16 2005-03-10 University Of Maryland Biotechnology Institute Bisphosphonates for prophylaxis and therapy against bioterrorism agents
CA2564562A1 (en) * 2004-04-26 2005-11-03 Innate Pharma Adjuvant composition and methods for its use
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
CA2602223A1 (en) * 2005-03-22 2006-10-05 Christian Belmant New class of yo t cells activators and use thereof
US8012466B2 (en) * 2008-01-31 2011-09-06 University Of Iowa Research Foundation Immunogenic compositions for activating γδ T cells
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy

Also Published As

Publication number Publication date
WO2010086617A3 (en) 2010-09-16
WO2010086617A2 (en) 2010-08-05
GB2467437A (en) 2010-08-04
GB201001521D0 (en) 2010-03-17

Similar Documents

Publication Publication Date Title
GB0919432D0 (en) Use
GB0910545D0 (en) Picturesafe
HK1166333A1 (en) Anti-bcma antibodies -bcma
TWI443910B (en) Anschluss-und verbindungsvorrichtung
EP2415386A4 (en) Endoscope
EP2462514A4 (en) Greenbooks
GB0902393D0 (en) Elaectric machine - modular
EP2515891A4 (en) 3-keto-n-propargyl-1-aminoindan
EP2380483A4 (en) Endoscope
HK1175476A1 (en) Cancer treatment
PL2443485T3 (en) Biomedical devices
GB0802116D0 (en) Treatment
GB201003863D0 (en) Spectropotometer
EP2405869A4 (en) Obesity treatment
TWI457337B (en) Furazanobenzimidazoles
PL2443486T3 (en) Biomedical devices
IL214232A (en) Tricyanoborates
GB0905568D0 (en) Taxling
IL216337D0 (en) Pyrazinylpyrazoles
GB0915552D0 (en) Cable-routing
HK1171017A1 (en) Quinolinyloxyphenylsulfonamides
GB0904835D0 (en) Trailersafe
TWI443103B (en) Compounds-801
EP2493820A4 (en) Water treatment
ZA201109517B (en) Treatment method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)